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Abstract 
Background: Globally, diabetes mellitus (DM) has risen dramatically over the past two decades and is expected to 
keep rising for the next 20 years. If uncontrolled it may lead to complications to the patients that could be prevented 
or delayed. The disease could be diagnosed and monitored by blood glucose and/or glycated hemoglobin (HbA1) 
testing. HbA1 can tell long term hyperglycemia of the last 2–3 months period and can predict the risk of diabetic 
complications; however, the use of glycated hemoglobin test in the country, specifically, in the study area is almost 
none. Therefore, this study had the aim of assessing glycemic control and describing the risk of complications among 
diabetic patients using glycated hemoglobin.
Methods: Cross-sectional study was conducted in Jimma University specialized hospital among 148 diabetic 
patients from May to July 2012. After the study was ethically approved, HbA1, random blood sugar (RBS), socio-demo-
graphic data and clinical information were collected from every diabetic patients who were willing to participate in 
the study among patients coming to the hospital for their routine follow up visits.
Results: Even though all the study participants were on diabetes treatment, majority of them were found to be poor 
glycemic control. It was found out that the mean HbA1 and RBS level of the participants were 7.6 % and 280 mg/dL 
(15.5 mmol/L), respectively. Using HbA1,5 9.5 % of the patients had poor glycemic control and these patients were 
considered to be at higher risk of developing complications. Among all the study subjects with poor glycemic control, 
70.8 % were within 15–30 years of age; 62.3 % were females; 60.8 % were urban dwellers; 67.4 % were illiterate; 69.6 % 
were with BMI less than 18.5 kg/m2, and 61.4 % were taking injectable drugs. Among 136 patients whose clinical his-
tory was reviewed, 52.9 % had one or more documented history of major microvascular complications: visual distur-
bance accounting for 21.3 %, nephropathy 19.1 % and peripheral neuropathy 13.2 %. Eighty-four had poor glycemic 
control of which 54.7 % had already documented history of one or more complications but the remaining 45.2 % had 
no documented history.
Conclusion: Even if all of the diabetic patients were on treatment, the mean HbA1 level as well as RBS level of the 
study subjects was above the normal range indicating poor glycemic control. More than half of diabetic patients in 
the hospital had poor glycemic control and were at higher risk of developing diabetic complications or they already 
developed the complications. Accordingly we recommended tracing the cause of this poor glycemic control for 
mitigating the problem.
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Background
Diabetes mellitus (DM) comprises a group of metabolic 
diseases resulting in hyperglycemia, either because the 
body does not produce enough insulin, or cells do not 
respond to the insulin that is produced or both. It can 
result in acute and chronic complications. Chronic com-
plications harm many parts of the body and majority of 
diabetes morbidity and mortality are associated to this 
complication. Hyperglycemia is an important etiologic 
factor of those complications [1–3].
Recurrent hyperglycemia is the diagnostic feature of 
DM. More specifically, a patient demonstrating any one 
of the following is diagnosed as having diabetes: symp-
toms of diabetes plus random blood sugar ≥200  mg/
dL (11.1  mmol/L) or fasting blood sugar ≥126  mg/dL 
(7 mmol/L) or 2-h plasma glucose during glucose toler-
ance test (GTT) ≥200 mg/dL (11.1 mmol/L) or glycated 
hemoglobin (Hb A1) ≥6.5 % [4, 5].
For assessing long-term glycemic control in people 
with diabetes, HbA1 is the standard and preferred test. In 
addition to its use for diagnosis, world health organiza-
tion (WHO) has endorsed the use of HbA1 as a screening 
test for persons at high risk of diabetes, and more impor-
tantly as a test for prediction of the risk of microvascular 
complications. It is formed by non-enzymatic bonding of 
adult hemoglobin (HbA) with glucose in the blood, i.e. 
irreversible glycation of adult hemoglobin. If hyperglyce-
mia stays for long, it leads to glycation of large number 
of HbA. This glycated HbA circulates for about 120 days 
which is equal to the lifespan of erythrocyte. Conse-
quently, its value reflects long-term glycemic exposure, 
representing the average glucose concentration over the 
last 8–12 weeks [1, 5, 6].
Globally, DM has risen dramatically over the past two 
decades, from an estimated 30 million cases in 1985–177 
million in 2000. It was estimated in 2010 that there were 
285 million people with type 2 diabetes making up about 
90 % of the cases. Its incidence is increasing rapidly and 
is estimated that this number will almost be doubled by 
2030. The greatest increase in the prevalence is expected 
to occur in Asia and Africa. In 2010, in sub-Saharan 
Africa (SSA), above 12 million people had diabetes, and 
330,000 people died from diabetes-related conditions. 
Moreover, access to standard diabetes management in 
SSA was extremely limited because of insufficient health-
care systems; scarcity of professionals with satisfactory 
training in diabetes diagnosis and treatment; scarcity or 
unaffordability of medication, and scarcity of diagnostic 
tools and other equipment [1, 6–8].
The magnitude of poor glycemic control in diabetic 
patients in different parts of the world is high. For 
instance, a study conducted in Malaysia showed 75.3 %, 
in Spain 45  %, in Jordan 65.1  % and in Ethiopia 94  % 
[9–12]. Moreover, different researchers had shown that 
poor glycemic control of diabetic patients leads to micro-
vascular and macrovascular complications. However, 
lowering HbA1 concentrations (by tight glycemic control) 
significantly reduces the rate of progression of microvas-
cular complications. For instance, dropping HbA1 from 
9.1–7.3  % reduces the risk of macrovascular disease by 
41 %, retinopathy by 63 % and nephropathy by 54 % and 
neuropathy by 60 %. Every increase in HbA1 can increase 
the cardiovascular event rate by up to 18  % and the 
microvascular event rate by up to 30 % [13–17].
Researchers around the globe have indicated that there 
are many contributing factors to poor glycemic control. 
These include older age, female sex, ethnic variation, 
drinking alcohol, higher BMI, smoking, longer duration 
of diabetes, lower physical activity, lack of adherence to 
diabetes management (such as diabetes self-care manage-
ment), and many others. A study conducted in Mekelle 
Ethiopia has also identified that scattered populations, 
shortage of drugs and insulin and lack of diabetes care 
team were the major factors behind those serious issues 
of diabetic control and complications [9, 12, 18].
Another study conducted in Ethiopia showed that there 
is high prevalence of both acute and chronic complica-
tions among diabetic cases, and indicated that only about 
1/3 of them receives standard diabetes care. Accordingly 
the study recommended that effective and efficient pre-
vention and control strategies should be designed and 
performed in the country. Similarly a study conducted in 
Jimma indicated that chronic complications were greater 
than 23 % and overall diabetes management at the hos-
pital were far below any recommended standards. The 
study proposed that urgent action to improve care for 
patients with diabetes is mandatory [19, 20].
For provision of standard care for the patients, objec-
tive information regarding the magnitude of poor 
glycemic control is needed; however, studies on the 
assessment of glycemic control using glycated hemo-
globin in Ethiopia are very scarce. To elucidate the few, 
in 1995 glycated hemoglobin was tested for 102 diabet-
ics who were seen at the outpatient clinic in Gondar in 
which 78 % of type 1 and 77 % of type 2 diabetic patients 
were poorly controlled. A study conducted to evaluate 
the glycemic control and load of complications in 105 
diabetic patients at Mekelle hospital in 2007 identified 
that only 6  % of the patients had good glycemic con-
trol. In 2002 another study conducted among diabetic 
patients at the outpatient diabetic clinic of Jimma Uni-
versity Hospital concluded the presence of overall poor 
glycemic control [9, 21, 22]. Moreover, another study 
indicated that none of the diabetic patients in Ethiopia 
had glycated hemoglobin test. The study also showed 
that none of the diabetic patients in Addis Ababa had 
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HbA1c determination for their glycemic control and only 
21  % of patients had access to blood glucose monitor-
ing at the same health institutions. It was found out that 
among the patients, only 5 % were able to do self-blood 
glucose monitoring at home and 51 % of patients didn’t 
have urine analysis, BUN, creatinine and lipid profile in 
the previous 1–2 years [23].
Therefore, this study was proposed to fill the gaps 
observed. Glycated hemoglobin test was used to deter-
mine level of glycemic control among diabetic patients 
and to assess risk of diabetic complications. This study 
was also aimed to introduce the test method for further 
routine use in the laboratory of the study area. Moreover, 
diabetic patients especially those who do not have access 
to routine monitoring of their blood glucose will benefit 
from the glycated hemoglobin test which assesses their 
long term glycemic control status, and this predicts the 
chance of having diabetic complications.
Methods
This cross sectional study was conducted among diabetic 
outpatients in Jimma University Specialized Hospital 
from 1 May to 31 July 2012. It was aimed to assess the 
glycemic control status of diabetic patients using glycated 
hemoglobin test and to determine risk of developing 
diabetic complication. The hospital is located in Jimma 
town, Oromia National Regional State at 353 km to the 
southwestern of Addis Ababa, the capital of Ethiopia. The 
hospital has 450 beds and is a teaching hospital that gives 
service to southwestern part of Oromia, part of south-
ern people nations and nationalities, as well as Gambella 
regions of Ethiopia. The hospital has separate chronic ill-
ness referral clinic in which diabetic patients are regularly 
monitored every Mondays and Tuesdays of the week.
Population for the study were all diabetic patients com-
ing to Jimma University Specialized Hospital diabetic 
clinic for their regular follow up and willing to partici-
pate in the study. Those diabetic patients who were blood 
transfused within the previous 3  months period were 
proposed to be excluded from the study.
A total of 148 diabetic patients registered in the dia-
betic clinic of the hospital and coming consecutively 
during the study were included. However, the minimum 
sample size determined using single proportion formula 
was 87 (using prevalence of HbA1  ≥  7  %  =  94  % [9], 
d-marginal error = 5 %).
About 5 ml of blood was collected for the determina-
tion of HbA1, RBS, creatinine and urea. HbA1 was deter-
mined from whole blood but RBS, creatinine and urea 
were from plasma. Therefore, one EDTA vacutainer tube 
for the whole blood and one for plasma was utilized from 
a single venipuncture of a single diabetic patient.
For RBS, creatinine and urea determination one of the 
two test tubes was centrifuged within 30  min of collec-
tion to separate the plasma. Plasma was used to measure 
glucose as per the ADA and WHO recommendations [6, 
16]. GOD-PAP method for glucose measurement using 
automated Clinical Chemistry analyzer at 450 nm wave-
length was utilized. Jaffe reaction method for creatinine 
and enzymatic urease method for urea determination 
was performed. Humastar 80 automated Clinical Chem-
istry analyzer with serial number of 201/79 Ref 16880 in 
the hospital laboratory was used for the measurement of 
the blood sugar, creatinine, and urea.
For the HbA1 determination, whole blood was mixed 
with a lysing reagent containing a detergent and borate 
ions. Elimination of the labile Schiff’s base was thus 
achieved during the hemolysis. The hemolysate was 
then mixed for at least 5  min with a weakly binding 
cation exchange resin. During this time, HbA0 (non gly-
cated HbA) binds to the resin. A special resin separa-
tor was used to remove the resin from the supernatant 
fluid which contained the HbA1 (glycated HbA). The 
glycohemoglobin percentage of total hemoglobin was 
determined by measuring the absorbance of the glycohe-
moglobin and of the total hemoglobin fraction at 415 nm 
in comparison with a standard glycohemoglobin prepara-
tion carried through the test procedure. CECIL CE 7200 
UV-Visble Spectrophotometer with serial number of 
137634 and S/W version of R0053 from Wagtech Inter-
national was used for the measurement of absorbance 
of the prepared samples and standards. Whole blood 
specimens were stored for maximum of 2 days at 2–8 °C 
before analysis. Whole blood specimens are stable for 
1 week at 2–8 °C [24, 25].
Other socio-demographic data such as age, sex, weight, 
height, ethnicity, educational status, duration of diabe-
tes, type of treatment and type of diabetes were gathered 
from the patients by structured interview and by looking 
to the clinical data from their charts. The socio-demo-
graphic data as well as the laboratory result were docu-
mented on the format specifically designed for each of 
148 diabetic cases.
Before they were processed, the collected data were 
cross-checked daily for completeness and then coded, 
categorized, and summarized. Descriptive statistics 
and inferential statistical tests using Chi square test 
and regression analysis were implemented. It was pro-
posed for variables that do not satisfy the assumptions 
of Chi square test to use the Fisher’s exact test instead of 
Pearson Chi square test to test the association between 
the dependent variable and the independent variables. 
Additionally variables with p value less than 0.25 in 
bivariate logistic regression analysis were nominated for 
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multivariate logistic regression analysis. p values  <0.05 
was taken as cut off value for significant association 
among the dependent and independent variables. Data 
analysis was performed using SPSS version 16.
The quality of the study was assured by running qual-
ity control material every day before running the sample. 
Moreover, trained data collectors were used to collect the 
data. Additionally preventive maintenance for the equip-
ment was undertaken and cold-chain was continuously 
monitored according to the SOP. SOP (for the sample 
collection, processing and analyzing) were strictly fol-
lowed so as to assure the quality of the study.
A preliminary study was performed for checking the 
easiest way of data collection procedure, client satisfac-
tion, and validity of the test kit of glycated hemoglobin 
before directly going to the real data collection on 5 % of 
the total study participants.
Ethical review
The ethical review board of Jimma University reviewed 
the research proposal and granted the ethical clearance 
for the researcher to undertake the study. The study par-
ticipants were informed about the objective, risks, ben-
efits and purpose of the study. Verbal consent was taken 
from the participants and only those who were willing to 
participate were included in the study. Confidentiality of 
information was assured and information was recorded 
anonymously.
Limitations of the study
HbA1 test may be altered by factors other than blood 
glucose (e.g., change in erythrocyte life span, ethnicity) 
and some conditions interfere with measurement (e.g., 
selected hemoglobinopathies).
For the random blood sugar testing there are many 
limitations such as difficulty to have exactly the same 
postprandial time for every patient under investigation, 
large biological variability, diurnal variation, sample not 
stable, numerous factors alter glucose concentrations 
(e.g., stress, acute illness). Moreover, RBS or FBS is less 
tightly linked to diabetes complications (than HbA1), 
and reflects glucose homeostasis at a single point in 
time.
Operational definition
1. Diabetic patients having HbA1 value greater than 7 % 
are considered to be at higher risk of developing dia-
betic complications.
2. Urban = Jimma town and other woreda towns.
3. Poor glycemic control  =  glycated hemoglobin 
level ≥ 7 %.
4. Hyperglycemia = blood glucose level above the nor-
mal range of 100 mg/dl.
Result
Though the minimum sample size determined for this 
study was 87, to increase the validity of the data, a total 
of 148 diabetic patients, of which 87 (58.8 %) were male 
were included in the study. The mean (±SD) age of the 
study participants was 48.5 (±15.7) with the least age of 
15 and the maximum 86 years.
From all the study subjects, 65 (43.9  %) were in the 
age range of 45–60  years; 87 (58.8  %) were males; 92 
(62.2  %) were from the urban; 123 (83.1  %) were mar-
ried; 85 (57.4 %) were Muslims; 95 (64.2 %) were Oromo; 
67 (45.3 %) were at primary educational level. All of the 
study subjects responded that they were on treatment. 
However, none of the patients was blood transfused 
within the last 3 months’ time (Table 1).
Glycated hemoglobin (HbA1  %), random blood sugar, 
creatinine and urea tests were performed for the entire 
148 of the study subjects. The mean (±SD) HbA1 % of the 
study subject was 7.6 (±1.9) and the median was 7.5 with 
the maximum value of 13.5. Among all the study sub-
jects, 88 (59.4 %) patients had poor glycemic control [of 
which 81(54.7 %) had poor and 7 (4.7 %) very poor] using 
the result of HbA1 (Table 2).
Glycemic control status of the study subjects was 
determined by the result of HbA1. According to the 
result, poor glycemic control was encountered differently 
among the independent variables of the study subjects. 
More than half of the study subjects had poor glyce-
mic control when viewed against every variable studied. 
Majority, [17 (70.8 %)] of those with the age range from 
15–30 years, 38 (62.3 %) of female patients, 7 (100 %) of 
the widowed, 11 (73.3 %) of those with duration of diabe-
tes from 11–15 years, 31 (67.4 %) of illiterate, 16 (69.6 %) 
of those with BMI less than 18.5 and 46 (61.4  %) of 
those taking injectable drugs had poor glycemic control. 
However, poor glycemic control among the categorized 
independent variables was statistically not significantly 
different from each other with p < 0.05 (Table 3).
The mean (±SD) random blood sugar (RBS) of 
this study subjects was 280  mg/dL (±139  mg/dL) or 
15.6  mmol/L (±7.7) and the median was 270  mg/dL or 
15moml/L. Seventy-one (48  %) of the patients were 
hyperglycemic and 26 (17.6 %) were extremely hypergly-
cemic. Fifty (33.8 %) had normal blood glucose level and 
only 1(0.7 %) had hypoglycemia using RBS testing. Using 
RBS testing result, poor glycemic control was encoun-
tered among 97 (65.5 %) of the patients (Table 2).
According to the result of multivariate analysis, 
patients with age >30–45 years were 0.26 times less likely 
in having poor glycemic control [AOR =  0.26, 95  % CI 
(0.04–1.58)] than patients with age range of 15–30 years. 
Females were 0.88 times less likely in having poor gly-
cemic control [AOR  =  0.88, 95  % CI (0.38–2.03)] than 
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males. Those patients with BMI  >  30 were 0.56 times 
less likely in having poor glycemic control [AOR = 0.56, 
95 % CI (0.08–3.85)] than those with BMI < 18.5. Those 
patients on injectable type of treatment format were 
0.51 times less likely in having poor glycemic control 
[AOR = 0.51, 95 % CI (0.06–4.01)] than those on combi-
nation of both oral and injectable format.
However, those who were married were 3.29 times 
more likely in having poor glycemic control [AOR = 3.29, 
95 % CI (0.51–21.11)] than single patients. Those patients 
having >10 upto 15  years of duration of DM were 5.04 
times more likely in having poor glycemic control 
[AOR = 5.04, 95 % CI (0.69–36.92)] than those <1 year. 
Those patients with educational level of grade 9–12 were 
3.89 times more likely in having poor glycemic control 
[AOR  =  3.89, 95  % CI (0.74–20.42)] than those having 
diploma and above (Table 4).
Clinical record or chart review was performed for 136 
patients regarding the history of complications. Accord-
ingly, 72 (52.9 %) of the patients had one or more history 
of microvascular chronic complications. Only 6 (8.3  %) 
patients of them had documented history of complica-
tions of less than 3  months duration but the remaining 
had greater than 3  months. The documented history 
of chronic complications such as visual disturbance, 
nephropathy, peripheral neuropathy and others was 28 
(20.6  %), 25 (18.4  %), 18 (13.2  %) and 3 (2.2  %), respec-
tively (Table 5).
Among those 136 patients whose clinical history were 
reviewed, 84 had high glycated hemoglobin level out of 
Table 1 Socio-demographic and  clinical characteristics 




 15–30 24 16.2
 >30 up to 45 34 22.9
 >45 up to 60 65 43.9
 >60 up to 75 18 12.2
 >75 up to 90 7 4.7
Sex
 Male 87 58.8
 Female 61 41.2
Residence
 Urban 92 62.2
 Rural 56 37.8
Marital status
 Single 16 10.8
 Married 123 83.1
 Divorced 2 1.4
 Widowed 7 4.7
Ethnicity
 Oromo 95 64.2
 Amhara 21 14.2
 Tigre 2 1.4
 Kafa 5 3.4
 Others 25 16.9
Religion
 Muslim 85 57.4
 Orthodox 51 34.5
 Protestant 10 6.8
 Catholic 2 1.4
Educational status
 Illiterate 46 31.1
 Grade 1–8 67 45.3
 Grade 9–12 22 14.9
 Diploma and Above 13 8.8
Duration of diabetes
 <1 year 11 7.4
 1–5 years 77 52.0
 >5 up to 10 years 39 26.4
 >10 up to 15 years 15 10.1
 >15 up to 20 years 3 2.0
 >20 years 3 2.0
Body mass index in kg/m2
 <18.5 or underweight 23 15.5
 18.5–24.9 or healthy weight 82 55.4
 >24.9–30 or overweight 36 24.3
 >30 or obese 7 4.7
Current treatment
 Injectables 75 50.7
 Oral 68 45.9
 Combination of both 5 3.4
Table 2 Glycemic control level by  both HbA1 and  RBS 
as  well as  laboratory indicators of  renal problem of  the 
study participants, JUSH Diabetic Clinic, 1 May 31 July, 
2012
Laboratory test results Frequency Percent
Glycated hemoglobin level in percentage
 <7 % (good glycemic control) 60 40.5
 7–11 % (poor glycemic control) 81 54.7
 >11.1 % (very poor glycemic control) 7 4.7
Random blood sugar (RBS) level in mg/dL
 <70 (hypoglycemic) 1 0.7
 70–200 (normoglycemic)l 50 33.8
 200–400 (hyperglycemic) 71 48.0
 >400 (extreme hyperglycemic) 26 17.6
Creatinine in mg/dL
 Normal (0.5–1.2 mg/dL) 106 71.6
 Abnormal (> 1.2 mg/dL) 42 28.4
Urea in mg/dL
 Normal (10–50 mg/dL) 103 69.6
 Abnormal (> 50 mg/dL) 45 30.4
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which 46 (54.8  %) had already documented history of 
one or more diabetic complications. However, of those 
whose clinical history were reviewed 52 (38.2  %) had 
normal glycated hemoglobin level, 26 (50.0 %) of which 
had already documented history of one or more diabetic 
complications.
Those [72 (52.9  %)] patients with documented his-
tory of diabetic complications were viewed against their 
socio-demographic characteristics. Accordingly, major-
ity [12 (66.7  %)] of the complications were seen among 
those with age >60 upto 75  years old, among male sex 
[44 (55.7 %)] and among the widowed [5(71.4 %)]. More-
over, the complications were mainly observed among 
those with DM duration of >10 upto 15  years old [10 
(71.4 %)], among those with educational status ≥diploma 
[7 (63.6  %)] and among those who use injectable treat-
ment format [39 (54.9 %)]. However, the presence of this 
documented history of diabetic complication among the 
categorized independent variables was statistically not 
significantly different from each other (p > 0.05) (Table 6).
Table 3 Glycated hemoglobin (HbA1) level versus different socio-demographic and clinical characteristics of study par-
ticipants, JUSH diabetic clinic, 1 May 31 July, 2012
Socio-demographic  
characteristics
Glycated Hemoglobin (HbA1 in %) level indicating glycemic control level
HbA1 < 7 % (good control) HbA1 ≥ 7 % (poor control) Total p value
Age
15–30 7 (29.1) 17 (70.8) 24 0.636
>30 upto 45 14 (41.2) 20 (58.8) 34
>45 upto 60 30 (46.2) 35 (53.8) 65
>60 upto 75 6 (33.3) 12 (66.7) 18
>75 upto 90 3 (42.9) 4 (57.1) 7
Sex
Male 37 (42.5) 50 (57.5) 87 0.556
Female 23 (37.7) 38 (62.3) 61
Marital status
Single 7 (43.8) 9 (56.2) 16 0.167
Married 52 (42.4) 71 (57.6) 123
Divorced 1 (50) 1 (50) 2
Widowed 0 (0) 7 (100) 7
Duration of DM in years
<1 5 (45.5) 6 (54.5) 11 0.613
1–5 29 (37.7) 48 (62.3) 77
>5 upto 10 19 (48.7) 20 (51.3) 39
>10 upto 15 4 (26.7) 11 (73.3) 15
>15 upto 20 1 (33.3) 2 (66.7) 3
>20 2 (66.7) 1 (33.3) 3
Educational status
Illiterate 15 (32.6) 31 (67.4) 46 0.305
Grade 1–8 28 (41.8) 39 (58.2) 67
Grade 9–12 9 (40.9) 13 (59.1) 22
≥Diploma 8 (61.5) 5 (38.5) 13
BMI in kg/m2
<18.5 7 (30.4) 16 (69.6) 23
18.5–24.9 34 (41.5) 48 (58.5) 82 0.742
>24.9–30 16 (44.4) 20 (55.6) 36
>30 3 (42.9) 4 (57.1) 7
Current treatment format
Injectables 29 (38.7) 46 (61.3) 75
Oral 29 (42.6) 39 (57.4) 68 0.889
Combination of both 2 (40) 3 (60) 5
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The mean (±SD) blood creatinine and urea tests, the 
renal function testing parameters, were 1.09  mg/dL 
(±0.44  mg/dL) and 30.6  mg/dL (±14.5  mg/dL), respec-
tively. High creatinine and urea test result indicat-
ing renal problem was encountered among 42 (28.4  %) 
and 45 (30.4  %) of the patients, respectively (Table  2). 
Creatinine result was compared with the documented 
history of complications and 56.1 % of those having his-
tory of nephropathy were having high creatinine level. 
This high creatinine result had statistically significant 
association with the documented history of nephropathy 
(Chi2 56.67, df 4, p = 0.00).
Discussion
It is an established fact that diabetes mellitus is a debilitat-
ing disease that can cause complications in those patients 
whose blood glucose level is not controlled. This study of 
assessment of glycemic control in diabetic patients has 
contributed in filling the gap of lack of laboratory test for 
glycemic control (glycated hemoglobin) and made the 
test familiar with professionals in the laboratory. Differ-
ent studies had elucidated that long-term glycemic con-
trol is assessed by glycated hemoglobin test. Moreover, 
long-term glycemic control status of the patients in the 
study setting was made clear for researchers.
The mean HbA1 of the present study is 7.6 % and this 
is consistent with the 8.5 % report from Jimma [26] but a 
bit smaller from the 11.3 % report from Mekelle [9]. The 
mean random blood sugar of the present study subjects 
is 280 mg/dL which is consistent with FBS of 228.1 mg/
dL in Jimma [26], FBS of 228.2 mg/dL in Jimma [27]. It 
is an already established fact that glycated hemoglobin 
level greater than 7  %, fasting blood sugar level greater 
than 126  mg/dL and random blood sugar level greater 
than 200 mg/dL are considered as poor glycemic control. 
All the reports indicated above including the report of 
the present study showed that the glycemic control of the 
study subjects is poor.
According to different literatures [13–16], those dia-
betic patients with poor glycemic control, especially with 
glycated hemoglobin greater than 7 %, are at higher risk 
of developing diabetic complications. This present study 
revealed that 59.5  % of the diabetic patients have HbA1 
test value greater than 7  %. This is consistent with the 
52.5 % report from Jimma [28], 63 % report from China 
[29] but lower than 94.7 % report from Mexico [30]. This 
poor glycemic control could arise from different reasons 
Table 4 Multivariate analysis of  the associations 
between  poor glycemic control using HbA1 and  different 
covariates of  study participants, JUSH Diabetic Clinic, 1 
May 31 July, 2012
Variables Patients with poor glycemic control level using 
HbA1 ≥ 7 %
No (%) Crude or (95 % CI) Adjusted or 
(95 % CI)
Age
 15–30 17 (19.3) 1 1
 >30 upto 45 20 (22.7) 1.82 (0.32–10.34) 0.26 (0.04–1.58)
 >45 upto 60 35 (39.7) 1.07 (0.21–5.55) 0.18 (0.03–1.12)
 >60 upto 75 12 (13.6) 0.87 (0.18–4.22) 0.39 (0.05–3.12)
 >75 upto 90 4 (4.5) 1.50 (0.25–8.97) 0.51(0.03–8.21)
Sex
 Male 50 (56.8) 1 1
 Female 38 (43.2) 0.82(0.42–1.59) 0.88 (0.38–2.03)
Marital status
 Single 9 (10.2) 1 1.00
 Married 71 (80.7) 1.06 (0.37–3.03) 3.29 (0.51–21.11)
 Divorced 1 (1.1) 0.78 (0.04–14.75) 1.53 (0.05–51.58)
 Widowed 7 (7.9) NA NA
Duration of DM in years
 <1 6 (6.8) 1 1
 1–5 48 (54.5) 1.38 (0.38–4.93) 2.01 (0.44–9.24)
 >5 upto 10 20 (22.7) 0.88 (0.23–3.36) 1.18 (0.24–5.88)
 >10 upto 15 11 (12.5) 2.29 (0.44–11.92) 5.04 (0.69–36.92)
 >15 upto 20 2 (2.3) 1.67 (0.115–24.26) 2.89 (0.154–54.22)
 >20 years 1 (1.1) 0.42 (0.03–6.06) 0.28 (0.01–12.33)
Educational status
 Illiterate 31 (35.2) 3.31 (0.92–11.85) 3.73 (0.79–17.84)
 Grade 1–8 39 (44.3) 2.23 (0.66–7.54) 3.45 (0.78–15.29)
 Grade 9–12 13 (14.8) 2.31 (0.57–9.41) 3.89 (0.74–20.42)
 ≥Diploma 5 (5.7) 1 1
BMI in kg/m2
 <18.5 16 (18.2) 1 1
 18.5–24.9 48 (54.5) 0.62 (0.23–1.66) 0.72 (0.23–2.27)
 >24.9–30 20 (22.7) 0.55 (0.18–1.65) 0.65 (0.17–2.49)
 >30 4 (4.5) 0.58 (0.10–3.33) 0.56 (0.08–3.85)
Current treatment format
 Injectables 46 (52.3) 1.057 (0.167–6.716) 0.51 (0.06–4.01)
 Oral 39 (44.3) 0.897 (0.141–5.717) 0.60 (0.08–4.84)
 Combination of 
both
3 (3.4) 1 1
Table 5 Distribution of  chronic diabetic complications 
of  the study participants, JUSH Diabetic Clinic, 1 May 31 
July, 2012
Type of diabetic complications Frequency Percent
Complications history not registered 64 47.1
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such as dietary non-compliance, lack of physical exercise, 
poor storage and usage of drugs, poor quality of drugs, 
poor prescription of drugs and any other. These factors 
could be categorized as patient factors, medication fac-
tors, and health care provider (professional) factors.
Different research [9, 12, 18] around the globe indi-
cated that older age, female sex, ethnic variation, drink-
ing alcohol, higher BMI, smoking, longer duration of 
diabetes, lower physical activity, scattered populations, 
shortage of drugs and insulin, lack of diabetes care team 
and lack of adherence to diabetes management are con-
tributing factors to poor glycemic control. In this study; 
however, it was found out that in every categorized study 
variables poor glycemic control is more than 50 % except 
in those having diploma and above in their educational 
status (poor control is 38.5 %). This poor control in this 
study is statistically not significantly different among the 
categories.
Among 136 patients whose clinical history were 
reviewed, 84 had high glycated hemoglobin level out of 
which 46 (54.8  %) had already documented history of 
one or more diabetic complications. However, of those 
whose clinical history were reviewed, 52 (38.2  %) had 
normal glycated hemoglobin level, 26 (50.0 %) of which 
had already documented history of one or more dia-
betic complications. It is an established fact that HbA1 
result can predict the risk of complication depending on 
the previous 3 months status of glycemic control of the 
patient. Even though researchers identified that increased 
glycated hemoglobin level could predict the presence of 
chronic complications, in this study it seems that those 
with increased HbA1 (54.8  %) had similar documented 
history of complication with those having normal HbA1 
(50 %). This could be explained by the fact that we found 
out only 8.3  % of those with documented history of 
complications had less than 3 months duration of docu-
mented complication. This means that about 91.7 % had 
duration of greater than 3 months period which is above 
the prediction limit of HbA1. Thus the above seeming 
similarity of documented history is not the real similarity. 
HbA1 can only predict the risk of complication depend-
ing on the previous 3 months status of glycemic control 
of the patient.
Seventy-two (52.9  %) of diabetic patients had one or 
more documented history of complications, majority of 
which were visual disturbance accounting 29 (21.3  %), 
nephropathy 26 (19.1  %) and peripheral neuropathy 18 
(13.2 %). This is consistent with report from Jimma [28] 
that showed 52.5 % of one or more documented chronic 
complications of which majority of the complications 
were visual disturbance accounting 33.8  %, neuropathy 
29.5 % and nephropathy 15.7 %.
Those documented complications [72 (52.9  %)] were 
compared against some socio-demographic charac-
teristics of the patients. Even though the categorized 
independent variables had no statistically significant 
difference in having complication, the increasing trend 
with age, with duration of DM, with BMI, is similar with 
other study conducted in Jimma [28] and in China [29] 
but in contrary when gender is considered. In this study, 
though the difference is not statistically significant, male 
Table 6 Clinical history of  diabetic complication status 
versus  socio-demographic and  clinical characteristics 




Presence or absence of documented 
history of diabetic complications
Present Absent Total p value
Age
 15–30 10 (43.5 %) 13 (56.5 %) 23 0.63
 >30 upto 45 15 (51.7 %) 14 (48.3 %) 29
 >45 upto 60 32 (54.2 %) 27 (45.8 %) 59
 >60 upto 75 12 (66.7 %) 6 (33.3 %) 18
 >75 upto 90 3 (42.9 %) 4 (57.1 %) 7
Sex
 Male 44 (55.7 %) 35 (44.3 %) 79 0.44
 Female 28 (49.1 %) 29 (50.9 %) 57
Marital status
 Single 5 (33.3 %) 10 (66.7 %) 15 0.33
 Married 61 (54.5 %) 51 (45.5 %) 112
 Divorced 1 (50.0 %) 1 (50.0 %) 2
 Widowed 5 (71.4 %) 2 (28.6 %) 7
Duration of DM in years
 < 1 4 (40.0 %) 6 (60.0 %) 10 0.59
 1–5 34 (48.6 %) 36 (51.4 %) 70
 >5 upto 10 20 (55.6 %) 16 (44.4 %) 36
 >10 upto 15 10 (71.4 %) 4 (28.6 %) 14
 >15 upto 20 2 (66.7 %) 1 (33.3 %) 3
 >20 2 (66.7 %) 1 (33.3 %) 3
Educational status
 Illiterate 23 (53.5 %) 20 (46.5 %) 43 0.56
 Grade 1–8 30 (47.6 %) 33 (52.4 %) 63
 Grade 9–12 12 (63.2 %) 7 (36.8 %) 19
 ≥Diploma 7 (63.6 %) 4 (36.4 %) 11
BMI in kg/m2
 <18.5 9 (42.9 %) 12 (57.1 %) 21 0.78
 18.5–24.9 42 (55.3 %) 34 (44.7 %) 76
 >24.9–30 18 (54.5 %) 15 (45.5 %) 33
 >30 3 (50.0 %) 3 (50.0 %) 6
Current treatment format
 Injectables 39 (54.9 %) 32 (45.1 %) 71 0.31
 Oral 32 (53.3 %) 28 (46.7 %) 60
 Combination of both 1 (20.0 %) 4 (80.0 %) 5
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had more recorded complication than female but it was 
in females in other studies [28, 29]. The reason for this 
discrepancy in gender needs further exploratory study.
Blood creatinine and urea tests were performed for all 
the 148 patients. The mean (±SD) of both renal function 
test parameters was, 1.09 (±0.44) for creatinine and 30.6 
(±14.5) for urea. Forty-two (28.4 %) patients had abnor-
mally high creatinine result indicating renal problem. 
This is in consistent with the already established fact that 
renal problem result in high creatinine.
Conclusion and recommendation
In conclusion, even if all of the diabetic patients are on treat-
ment, the mean glycated hemoglobin level (HbA1) as well as 
random blood sugar (RBS) level of the study subjects were 
above the normal range indicating poor glycemic control.
More than half of all diabetic patients in Jimma Univer-
sity Specialized Hospital had poor glycemic control and 
were at higher risk of developing diabetic complications 
and/or even already developed the complications. There-
fore, it is very important to look for ways of alleviating 
this critical situation.
Accordingly it is recommended to trace the cause of 
such alarming rate of poor glycemic control by conduct-
ing different researches so as to alleviate the problem.
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